主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VKTX
#1306
Viking Therapeutics, Inc. - Common Stock
32.7
4
USD
+1.71%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+1.71%
每月变动
+7.41%
6个月变化
-9.41%
年变化
+18.11%
前一天收盘价
32.1
9
Open
32.7
4
最低价
32.7
4
High
32.7
4
交易量
121
市场
US Stock Market
医疗保健
VKTX
展开完整图表
完整图表
Financials
概览
声明
统计
每季度
年度
Market Capitalization
3.8 B
Employee
59
Founded
2012
CEO
Brian Lian
Website
www.vikingtherapeutics.com
Headquarter
Delaware, United States
FIGI
BBG006LGV869
Industry
生物技术
总收入
净利润
每股基本收益(基本 EPS)
总债务
自由现金流
现金及现金等价物
新闻
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market